ASTRAZENECA PLC DL-,25/ GB0009895292 /
04/11/2024 19:31:52 | Chg. -0.30 | Volume | Bid19:50:11 | Ask19:50:11 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
131.10EUR | -0.23% | 0 Turnover: 0.00 |
-Bid Size: - | -Ask Size: - | 204.44 bill.EUR | - | - |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
CEO |
---|
Pascal Soriot |
Management board |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Supervisory board |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg, Anna Manz |
Company data
Name: | AstraZeneca plc |
Address: | 1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom |
Phone: | 0800 783 0033 |
Fax: | +44-20-7604-8151 |
E-mail: | Medical.InformationU...eca.com Medical.InformationUK@astrazeneca.com |
Internet: | www.astrazeneca.com |
Industry: | Healthcare |
Sector: | Pharmaceutical Industry |
Sub sector: | Pharmaceuticals |
End of financial year: | 31/12 |
Free Float: | - |
IPO date: | 06/04/1999 |
Investor relations
Name: | Andy Barnett |
IR phone: | +44 (0)20 3749 5000 |
IR Fax: | - |
IR e-mail: | CorporateAccess@astrazeneca |
Main Shareholders
Others | 77.64% | |
BlackRock, Inc. | 6.51% | |
Wellington Management Company LLP | 4.20% | |
Wellington Management Group LLP | 4.20% | |
The Capital Group Companies, Inc | 4.12% | |
Investor AB | 3.33% |